Alliance Pharma Share Discussion Threads

[pimpernel4] 20/3/2013 14:43

Good to see the astute Mr Wray further increasing his substantial holding here.

[mazarin] 15/3/2013 19:20

In Feb I had an inckling the share price might start stirring and sure enough it did. Results are next Thursday and UK Investor Show presentation is due 13th April 2013. So things should be looking up.

[mechanical trader] 15/3/2013 09:25

APH Alliance Pharma. Results on the 21st of this month. Thursday. Think profits will beat broker forecast.. just added.

[mechanical trader] 13/2/2013 08:59

APH

Not far off breaking out.

BUY placed on it by SCSW tip sheet
this weekend.

Personaly Im looking for a bolt on
before results on 21st of March...

see historical item below.....

Alliance Pharma gets more ammo for acquisition drive
15th Jan 2013, 1:16 pm by Philip Whiterow

Alliance has £13.5mln to spend following the latest injection of funds. Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.

The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln.

Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds.

Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline.

If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts.

"P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating," said Numis.

Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol.

"As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations," the specialist pharmaceutical group said.

Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year.

Sales were hit by Sanofi Pasteur's temporary suspension of the manufacture of Immucyst in June, but Hydromol's record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln.

Last year's acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said.

Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update.

The company's business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products.

Shares rose by 4% to 33.5p.

[mazarin] 07/2/2013 14:40

Company proposes to have Analysts Briefing on results day at 10.00am Thursday 21 March 2013 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN on. I think we'll start to see movement here soon.

[montyhedge] 24/1/2013 07:49

Oh no, that means its going to fall then.

[lucky_punter] 18/1/2013 08:42

expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.

[cisk] 15/1/2013 09:15

2vdm, indeed this is good news and I'm hopeful that 2013 will be a good year for alliance, hopefully with production of ImmuCyst resuming later this year (although may be too late to have a meaningful impact on the bottom line).

I'm still wondering if Alliance will be able to get any comeback from Sanofi, given they bought the rights for the product, surely they would have some comeback if that product was not being manufactured for a prolonged period.

Regardless of this, I still expect solid progress this year, and with £13.5m of firepower I get the feeling that we can expect a few more acquisitions in the coming months.

GLA

Cisk

[2vdm] 15/1/2013 08:52

RNS out re anticipated profits fye Dec 2012. "Above expectations" Good news and will be interesting to see final results in March. Maybe we will get more news of further acquisitions as finance available in line with bod's plans.

[petethehippy] 08/1/2013 12:03

What is the sales growth of this company?
I read 16% growth.
Seems to be out of kilter with a PE of 7.

[mazarin] 02/1/2013 09:53

I'm now waiting to hear for news of when Toronto's Pasteur Plant is due to be back 'on stream' and resumption of Immuncyst production, that so badly hit APH during summer 2012. In July it was then forecast not be ready until end of 2013, I hoping it will be earlier.

[n69eil] 18/11/2012 16:45

Directors taking A LOT of profit instead.

[n69eil] 18/11/2012 16:45

Directors taking A LOT of profit instead.

[montyhedge] 10/11/2012 18:53

Director sells, time to abandon ship.

[mazarin] 31/10/2012 10:51

This news may account for the recent lull in current share price uptrend, however glad today to see modest northerly movement.
"Anthony Booley, Executive Director, sold 800,000 shares in the company on the 25th October 2012 at a price of 30.50p. The Director now holds 4,610,723 shares."

[this_is_me] 19/10/2012 09:49

It is hardly a transforming dea;l, but buying a firm at a P/E of about 5 can't be a bad deal.

[cisk] 19/10/2012 09:28

2vdm, sounds like a nice little deal for APH.

John Dawson is a canny CEO so I'm sure that he will have done his homework on this one. Good to see that it's earnings enhancing in the 1st year also.

[2vdm] 19/10/2012 08:15

RNS out.Well it appears that this is a ready made fit for Alliance. Profit for the 12 months to Match 2012 declared at 2.1m "before directors emoluments". Would be useful to know what the directors were paid and any planned "golden goodbyes/pay offs" if any, when the current directors of Opus leave in 6 months time. Also what will the financing costs be on the drawdown facility , to see what the company is left with as a net contributor to Alliances bottom line. Assuming APH has done their homework, this could bode well for the future, expanding its product range, as planned.

[napoleon 14th] 25/9/2012 08:12

Sanofi - lots of bad vibes inside the company. Plans of 900 redundancies by 2015.
Ee's complaining of a lack of investment & research & a policy of "easy markets" as the main thrust of the company.
It's all over the news channels here (France) this a.m.

I hope APH will go for compensation & get it....

[lucky_punter] 03/8/2012 13:37

Alliance Pharma (LON:APH) is taking its first major steps into Europe after acquiring a trio of antimalarial brands from pharmaceutical heavyweight AstraZeneca (LON:AZN).
Alliance's wholly owned subsidiary Alliance Pharmaceuticals will sell Paludrine, Avloclor and Savarine, mainly in the UK and France, after paying £4.2 million for the set.

[mazarin] 02/8/2012 07:28

At last today Alliance Pharmaceuticals has announced its acquisition of the antimalarial brands Paludrine(TM), Avloclor(TM) and Savarine(TM) from Astrazeneca UK Limited for £4.2M with additional £1M in further payments over next 3 years (sales dependant). APH expects this deal to generate incremental contribution before financing costs of approx.£1.1M per annum.

Have been expecting such an acquisition for some time, as strongly hinted at in the Company's recent TS, along with others, which hopefully now may help to give the share price a much needed boost.

It will be quite interesting to see what 'the markets and analysts' now make of this deal.